New drug duo aims to stop head & neck Cancer's return

This study is for adults with HPV-positive head and neck cancer who have finished their main treatment but still have tiny traces of cancer in their blood. It will test if adding a new drug called fianlimab to an existing immunotherapy (cemiplimab) works better than the single drug alone at keeping the cancer from coming back. Researchers will compare the two groups to see which approach leads to longer periods without the cancer returning and is safe for patients.